Latest Boehringer Ingelheim Stories
RIDGEFIELD, Conn., Nov. 9, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the launch of HepCRedefined.com, an online portal to help improve the lives of those living with the hepatitis C virus (HCV) through education, information and understanding. HepCRedefined.com aims to redefine the HCV journey by providing downloadable and shareable resources to healthcare providers, advocates, caregivers and patients. To view the multimedia assets associated...
RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 8, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the clinical trial enrollment of patients for CAROLINA (Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes) has been completed. Linagliptin is currently the only DPP-4 inhibitor that is being compared to a sulfonylurea in a long-term cardiovascular (CV) outcome study....
RIDGEFIELD, Conn., Nov. 7, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced interim results from the RELY-ABLE(®) trial, a long-term extension of the RE-LY(®) study. During more than two years of randomized follow-up, key safety outcomes such as major bleeding, total bleeding and life threatening bleeding were similar to the results of the dabigatran 110mg* and 150mg arms of the pivotal RE-LY trial that evaluated Pradaxa(®) (dabigatran etexilate...
RIDGEFIELD, Conn., Nov. 7, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that it is conducting a nationwide voluntary recall of a single manufacturing lot of Pradaxa(®) (dabigatran etexilate mesylate), 75mg 60 US, NDC 0597- 0149-54, lot 201900, Exp January 2015. PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). The recall is limited to this one lot number. (Photo:...
RIDGEFIELD, Conn., Nov. 2, 2012 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today announced the results of a Mini-Sentinel assessment that indicates bleeding rates associated with new use of Pradaxa(®) (dabigatran etexilate mesylate) capsules do not appear to be higher than bleeding rates associated with new use of warfarin, which is consistent with observations from the pivotal RE-LY(®) trial. The Mini-Sentinel assessment evaluated new information about the risk of...
UPPSALA, Sweden, October 29, 2012 /PRNewswire/ -- Beactica, the Swedish drug discovery company with world-leading expertise in molecular interactions, today announced its contribution to a key paper in the Journal of Pharmacology and Experimental Therapeutics*. As part of a collaboration with Boehringer Ingelheim, Beactica scientists provided important insights into the interactions between afatinib (BIBW 2992) and members of the ErbB receptor family. The results presented in...
RIDGEFIELD, Conn., Oct. 29, 2012 /PRNewswire/ -- On average, every hour, 15 people in the United States (U.S.) will suffer a stroke caused by atrial fibrillation (AFib), a type of irregular heartbeat. In support of World Stroke Day, Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) has launched 15 Every Hour, a new campaign to educate people about the seriousness of AFib-related strokes, which are nearly twice as likely to be deadly or severely disabling as non-AFib-related strokes....
BALTIMORE, Oct. 25, 2012 /PRNewswire/ -- The healthcare fraud case that Boehringer Ingelheim Pharmaceuticals Inc. settled today with the government for $95 million was due in large measure to a former Boehringer Ingelheim sales representative-turned-whistleblower who made extraordinary efforts to stop Boehringer Ingelheim's pharma marketing practices that allegedly defrauded Medicare and other government healthcare programs and promoted uses of its drugs that endangered patients'...
The Web’s largest source for information on Pradaxa legal news, research and side effects is available at the Pradaxa Resource Center. Visit http://www.Pradaxa-lawsuits.org Dallas, TX (PRWEB) October 20, 2012 The Journal for The American Medical Association last month warned that the FDA may have rushed approval of the drug Pradaxa, overlooking key Pradaxa side effects like early trials showing there was no reversal agent for Pradaxa internal bleeding. The news comes after an FDA...
BERLIN, Oct. 18, 2012 /PRNewswire/ --caprotec bioanalytics GmbH announced today a restructuring of its senior management and the appointment of Dr. Jonathan Turner as Managing Director and Chief Executive Officer. Dr. Turner joins caprotec as a highly regarded pharmaceutical executive and has held a number of senior management positions at global pharmaceutical companies, including Boehringer Ingelheim, AstraZeneca PLC and Schering AG. Prof. Dr. Hubert Koester, Founder and previous...
